Alkermes plc (NASDAQ: ALKS) announced it will present additional data from its Vibrance-1 phase 2 study of alixorexton for narcolepsy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE